Application of N-of-1 Rheumatoid Arthritis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06016517 |
Recruitment Status :
Not yet recruiting
First Posted : August 29, 2023
Last Update Posted : March 28, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The goal of this N-of-1 study is to learn about treatment for individual patients who have rheumatoid arthritis (RA,) for which many treatments are available. The treatments are different in how they work, the way they are given, side- effects, and cost. While treatment guidelines are available, finding the best treatment order of treatments is often based on physician choice. The main question this study aims to answer are:
- What are the effects of different treatments on RA symptoms and condition for each individual patient
- What is the effectiveness of different treatments across all patients enrolled in the N-of-1 study
Participants will be enrolled and randomized to a sequence of three U.S. Food and Drug Administration (FDA) approved RA medications: 1. adalimumab, 2. sarilumab, and 3. upadacitinib. Participants will be asked to complete questionnaires about their condition and quality of life weekly (either in clinic or remotely) and report their level of pain daily (remotely).
Condition or disease | Intervention/treatment |
---|---|
Arthritis, Rheumatoid | Drug: Adalimumab Drug: Sarilumab Drug: Upadacitinib |
Study Type : | Observational |
Estimated Enrollment : | 18 participants |
Observational Model: | Other |
Time Perspective: | Prospective |
Official Title: | Application of the N-of-1 Trial Design in Rheumatoid Arthritis |
Estimated Study Start Date : | May 15, 2024 |
Estimated Primary Completion Date : | May 15, 2025 |
Estimated Study Completion Date : | May 15, 2025 |
- Drug: Adalimumab
40 mg subcutaneously every 2 weeks with oral placebo once dailyOther Name: Humira
- Drug: Sarilumab
200 mg subcutaneously every 2 weeks with oral placebo once dailyOther Name: Kevzara
- Drug: Upadacitinib
15 mg orally once daily with subcutaneous placebo injection every 2 weeksOther Name: Rinvoq
- Change in Disease Activity Score (DAS) 28 [ Time Frame: Baseline and at week 4, 8 and 12 ]Evaluates patient and physician overall assessment of disease activity, including the number of swollen and painful joints (out of 28 joints),
- Change in The Routine Assessment of Patient Index Data 3 (RAPID3) [ Time Frame: Baseline and at week 4, 6, 8, 10 and 12 ]Assessment of a) function, b) pain, and c) patient global estimate of status
- Change in American College of Rheumatology 20 (ACR20) [ Time Frame: Baseline and at week 4, 8 and 12 ]≥20% fewer tender and swollen joints and ≥20% improvement in three of five other domains; a) patient global assessment, b) physician global assessment, c) functional questionnaire, d) pain score, and f) erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP)
- Change in American College of Rheumatology 50 (ACR50) [ Time Frame: Baseline and at week 4, 8 and 12 ]≥50% fewer tender and swollen joints and ≥20% improvement in three of five other domains; a) patient global assessment, b) physician global assessment, c) functional questionnaire, d) pain score, and f) erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP)
- Change in American College of Rheumatology 70 (ACR70) [ Time Frame: Baseline and at week 4, 8 and 12 ]≥70% fewer tender and swollen joints and ≥20% improvement in three of five other domains; a) patient global assessment, b) physician global assessment, c) functional questionnaire, d) pain score, and f) erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP)
- The Medical Outcome Study Short-Form 12- item Health Survey (SF-12) [ Time Frame: Baseline and at week 4, 6, 8, 10 and 12 ]General Health Questionnaire
- The Patient-Reported Measure of Physical Function (PROMIS) PF10a [ Time Frame: Baseline and at week 4, 6, 8, 10 and 12 ]Patient self- assessment of function
- Treatment Burden Questionnaire (TBQ) [ Time Frame: At End of Treatment ]Assessment of the burden associated with taking medicine, self-monitoring, laboratory tests, doctor visits, need for organization, administrative tasks, following advice on diet and physical activity, and social impact of treatment.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
-
• Newly diagnosed adult-onset Rheumatoid Arthritis (RA) as defined by the American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) 2021 Criteria for the Classification of RA
- Moderately to severely active RA defined as the presence of at least 6/68 tender joints and at least 6/66 swollen joints
- C-reactive protein (CRP) or high-sensitivity C-reactive protein (hsCRP) measurement ≥ 1 time the upper limit of normal
- First-line therapy with MTX for at least the 12 weeks prior to study entry with a continuous, non-changing dose for at least 8 weeks prior to study entry but continue to exhibit active RA
- Had to discontinue MTX due to intolerability or toxicity, irrespective of treatment duration
- Have never received adalimumab, sarilumab, upadacitinib prior to first dose of study drug.
- Provision of informed consent
- Stated willingness to comply with all study procedures and availability for the duration of the study
- 18 years of age or older
- Ability to take oral medication and be willing to adhere to the three treatment periods
- Patients are eligible whether their disease responded adequately or inadequately to first-line MTX or if they were intolerant to first-line MTX.
Exclusion Criteria:
-
• History of any arthritis with onset prior to age 17 years or current diagnosis of inflammatory joint disease other than RA
- Has received intra-articular, intravenous, intramuscular corticosteroids within 28 days prior to baseline
- Known allergic reactions to components of any of the three biologic agents
- Is currently receiving corticosteroids at doses > (greater than) 10 mg per day of prednisone (or equivalent) or have been receiving an unstable dosing regimen of corticosteroids within 2 weeks of study entry or within 6 weeks of planned randomization
- Has experienced any of the following within 12 weeks of study entry: myocardial infarction, unstable ischemic heart disease, stroke, or have New York Heart Association stage IV heart failure
- Tuberculosis infection
- Hepatitis B or C infection
- History of venous thromboembolic event (deep vein thrombosis, pulmonary embolism)
- Has a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute a risk or could interfere with the interpretation of data
- Has an estimated glomerular filtration rate (eGFR) based on the most recent available serum creatinine of < (less than) 40 milliliter per minute per 1.73 m^2 (mL/min/1.73 m^2)
- Has a history of chronic liver disease with the most recent available aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >1.5 times the ULN or the most recent available total bilirubin ≥1.5 times the ULN
- Has a history of, lymphoproliferative disease; or have signs or symptoms suggestive of possible lymphoproliferative disease, including lymphadenopathy or splenomegaly; or have active primary or recurrent malignant disease; or have been in remission from clinically significant malignancy for <5 years
- Has been exposed to a live vaccine within 12 weeks prior to planned randomization or are expected to need/receive a live vaccine during the course of the study (with the exception of herpes zoster vaccination)
- Has a current or recent clinically serious viral, bacterial, fungal, or parasitic infection
- Has had symptomatic herpes zoster infection within 12 weeks prior to study entry
- Is immunocompromised and, in the opinion of the investigator, are at an unacceptable risk for participating in the study
- Has a history of active hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)
- Has evidence of active or latent tuberculosis (TB)
- Current hospitalization or requiring hospital admission at screening
- Pregnant or breastfeeding
- Participation in another therapeutic clinical trial for RA
- Lack of internet access to telehealth platform
- Non-English speaking participants
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06016517
Contact: Dorothy Dulko | 6176365009 | ddulko@tuftsmedicalcenter.org |
United States, Massachusetts | |
Tufts Medical Center | |
Boston, Massachusetts, United States, 02111 |
Responsible Party: | Tufts Medical Center |
ClinicalTrials.gov Identifier: | NCT06016517 |
Other Study ID Numbers: |
00003917 |
First Posted: | August 29, 2023 Key Record Dates |
Last Update Posted: | March 28, 2024 |
Last Verified: | March 2024 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Arthritis Arthritis, Rheumatoid Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Connective Tissue Diseases Autoimmune Diseases Immune System Diseases Adalimumab |
Upadacitinib Tumor Necrosis Factor Inhibitors Anti-Inflammatory Agents Antirheumatic Agents Janus Kinase Inhibitors Protein Kinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |